Form 1 340BRegistration-Covered Entities All Other Revised

340B Drug Pricing Program Forms

340BRegistration-Covered Entities All Other Revised

340B Registration for all other covered entities

OMB: 0915-0327

Document [pdf]
Download: pdf | pdf
Dept. of Health and Human Services, Health Resources and Services Administration, HealthCare Systems Bureau
OMB No. 0915-XXXX; Expiration Date: XX/XX/XXXX

INSTRUCTIONS FOR COMPLETING THE 340B REGISTRATION FORM
(for use by Black Lung Clinics, Consolidated Health Center Programs, Family Planning entities
authorized under Title X, Federally Qualified Health Center Look-alikes, FQHC638,
Comprehensive Hemophilia Treatment Centers, Native Hawaiian Health Care Programs, Ryan
White Programs, Sexually Transmitted Disease entities authorized by Section 318, Tuberculosis
entities authorized by Section 317,and Urban Indian Programs – specific eligibility requirements
are posted on the OPA website)
While an organization may be eligible to participate in the 340B Program by virtue of its status (i.e., receiving a grant
from an eligible program), it must notify the Office of Pharmacy Affairs (OPA) of its intention to participate by
completing and submitting a signed original of the “340B Program Registration Form for Covered Entities.“ Once the
OPA receives, verifies, and processes this information, the entity will be eligible to purchase pharmaceuticals at the
340B price beginning the next calendar quarter. If your organization has been awarded a qualifying grant recently, you
may want to include a copy of your Notice of Grant Award to expedite the processing of your form.
This registration form must be completed and submitted according to the established deadlines that are published
on the OPA website (www.hrsa.gov/opa). The registration process is not complete unless the registration form has
been completed in its entirety (all requested information is filled in on the form) and all required supporting
documentation is submitted on the same day to OPA. Incomplete packages will not be processed.
NOTE ON SIGNATURES – the Registration Form must be signed by the Authorizing Official of the covered entity.
The authorizing official may be the President, Chief Executive Officer, Chief Operating Officer, Chief Financial Officer,
or Program Director. Forms that are signed by an individual that OPA determines is not an acceptable representative
will not be processed. If you are in doubt regarding the acceptability of a signature, please contact OPA prior to
submission of your registration form. Please include the title, telephone number, and e-mail address of the individual
who is signing.
NOTE ON SHIPPING ADDRESSES – complete this section ONLY if your pharmaceuticals will be shipped to an
address that is different from the covered entity address. However, do NOT use this section to provide information for
a contracted pharmacy arrangement. Use the form found at this link for contracted pharmacy information.
Accurate information on the entity should always be reflected on the OPA website. It is the covered entity’s
responsibility to notify OPA of any changes in writing by submitting the official 340B Program change request found at
this link.
Once your form has been processed, the OPA will notify you (at the e-mail address that you provide on the Program
Registration Form) of your effective date in the 340B Program and provide you with your 340B identification number, a
unique number that OPA assigns to each covered entity. Please use this number in all correspondence to OPA. This
is the number used by manufacturers, wholesalers, and others to search the OPA database to verify your participation
in the 340B program. It is the entity's responsibility to tell its wholesaler or manufacturer that it is registered for 340B
prices when it places an order. You may view the information for your entity on the OPA website by entering the 340B
ID number in the field labeled “340B ID. Entities will not see their 340B identification number in the database
immediately after approval. Approved 340B identification numbers will appear in the database at the start of the
upcoming quarter.

This registration form must be completed and submitted according to the established deadlines that are published on the OPA website (www.hrsa.gov/opa).

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently
valid OMB control number. The OMB control number for this project Is 0915-XXXX. Public burden is estimated to average XX minutes per respondent, including the time
for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send
comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance
Officer, 5600 Fishers Lane, Room 14-33, Rockville, Maryland 20857.

Dept. of Health and Human Services, Health Resources and Services Administration, HealthCare Systems Bureau
OMB No. 0915-XXXX; Expiration Date: XX/XX/XXXX

OFFICE OF PHARMACY AFFAIRS
340B PROGRAM REGISTRATION FORM FOR COVERED ENTITIES
Acknowledgement of Covered Entity Participation in Outpatient Discount Drug Pricing under Section 340B of the Public
Health Service Act.

I. Covered Entity Information:
Covered Entity Name: ______________________________________________________________________
Medicare Provider Number: __________________________________________________________________
Hospital Street Address: ____________________________________________________________________
City: _______________________________________________ State: _____________ ZIP: _____________
Billing Address (if different): ________________________________________________________
City: _______________________________________________ State: _____________ ZIP: _____________
Shipping Address (if different): ______________________________________________________
City: _______________________________________________ State: _____________ ZIP: _____________
Entity Type: (see next page for list of codes)

_________________________________________________

UDS or Grant Number: _________________________________________________

II. Medicaid Billing Information: You must answer the following question regarding Medicaid billing.
Will you bill Medicaid for drugs purchased through the 340B Drug Pricing Program?
Yes 
No 
If “Yes,” please provide the Pharmacy/Clinic Medicaid Provider Number(s) and/or National Provider Identifier(s) (NPI)
(please include the number(s) and State):
Medicaid Provider Number(s) _______________________ and/or_____________________________
National Provider Identifier(s) _______________________and/or______________________________
If you bill Medicaid for pharmaceuticals that may be subject to a payment of a Medicaid rebate to a state, you must
submit to OPA the pharmacy Medicaid number and/or clinic Medicaid number and/or NPI which is used to bill Medicaid
for outpatient drugs. If you are unsure of your pharmacy Medicaid number and/or NPI, please check with your State
Medicaid agency. It is important that your Medicaid billing status in our database is accurate to prevent Medicaid
rebates on drugs that were sold to a covered entity at a discounted price. If you bill at an all-inclusive rate, which
includes pharmaceuticals, or if you do not bill Medicaid, state N/A (Not Applicable) which is entered in our database.
You should notify OPA prior to any change in your Medicaid billing status. For more information, go to:
http://www.hrsa.gov/opa/medicaidexclusion.htm

This registration form must be completed and submitted according to the established deadlines that are published on the OPA website (www.hrsa.gov/opa).

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently
valid OMB control number. The OMB control number for this project Is 0915-XXXX. Public burden is estimated to average XX minutes per respondent, including the time
for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send
comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance
Officer, 5600 Fishers Lane, Room 14-33, Rockville, Maryland 20857.

Dept. of Health and Human Services, Health Resources and Services Administration, HealthCare Systems Bureau
OMB No. 0915-XXXX; Expiration Date: XX/XX/XXXX

III. Designated 340B Contact and Authorizing Official Information:
340B Contact Name: _________________________________________________________________
Title: ______________________________________________________________________________
Phone: _______________________

Ext. __________

Fax: _____________

Email Address: ______________________________________________________________________
Covered Entity Authorizing Official (Must be authorized to legally bind covered entity (e.g., CEO, CFO, COO))
Name: _________________________________________________________________
Title: ______________________________________________________________________________
Phone: _______________________

Ext. __________

Fax: _____________

Email Address: ______________________________________________________________________

This registration form must be completed and submitted according to the established deadlines that are published on the OPA website (www.hrsa.gov/opa).

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently
valid OMB control number. The OMB control number for this project Is 0915-XXXX. Public burden is estimated to average XX minutes per respondent, including the time
for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send
comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance
Officer, 5600 Fishers Lane, Room 14-33, Rockville, Maryland 20857.

Dept. of Health and Human Services, Health Resources and Services Administration, HealthCare Systems Bureau
OMB No. 0915-XXXX; Expiration Date: XX/XX/XXXX

IV. Signed Agreement:
The undersigned represents and confirms that he/she is fully authorized to legally bind the covered entity and certifies
that the contents of any statement made or reflected in this document are truthful and accurate.
The undersigned further acknowledges the 340B covered entity’s responsibility to abide by the following:
As an Authorized Official, I certify on behalf of the covered entity that:
(1) all information listed on the 340B Program database for the covered entity will be complete, accurate, and correct;
(2) the covered entity will meet all 340B Program eligibility requirements;
(3) the covered entity will comply with all requirements and restrictions of Section 340B of the Public Health Service
Act and any accompanying regulations or guidelines including, but not limited to, the prohibition against duplicate
discounts/rebates under Medicaid, and the prohibition against transferring drugs purchased under 340B to anyone
other than a patient of the entity;
(4) the covered entity will maintain auditable records demonstrating compliance with the requirements described in
paragraph (3) above;
(5) the covered entity has systems/mechanisms in place to ensure ongoing compliance with the requirements
described in (3) above;
(6) if the covered entity uses contract pharmacy services, that the contract pharmacy arrangement will be performed in
accordance with OPA requirements and guidelines including, but not limited to, that the covered entity obtains
sufficient information from the contractor to ensure compliance with applicable policy and legal requirements, and the
hospital has utilized an appropriate methodology to ensure compliance (e.g., through an independent audit or other
mechanism);
(7) the covered entity acknowledges its responsibility to contact OPA as soon as reasonably possible if there is any
material change in 340B eligibility and/or material breach by the covered entity of any of the foregoing; and
(8) the covered entity acknowledges that if there is a breach of the requirements described in paragraph (3) that the
covered entity may be liable to the manufacturer of the covered outpatient drug that is the subject of the violation, and,
depending upon the circumstances, may be subject to the payment of interest and/or removal from the list of eligible
340B entities.

Signature of Authorizing Official:

Date:

_____________________________________________________________________________________________

This registration form must be completed and submitted according to the established deadlines that are published on the OPA website (www.hrsa.gov/opa).

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently
valid OMB control number. The OMB control number for this project Is 0915-XXXX. Public burden is estimated to average XX minutes per respondent, including the time
for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send
comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance
Officer, 5600 Fishers Lane, Room 14-33, Rockville, Maryland 20857.

Dept. of Health and Human Services, Health Resources and Services Administration, HealthCare Systems Bureau
OMB No. 0915-XXXX; Expiration Date: XX/XX/XXXX

List of Covered Entity Type Codes
Please select from the list below and enter the appropriate code(s) for your entity on the
Registration Form under “Entity Type.” You should enter all codes for which your
organization is eligible as the scope of your grant may determine the eligibility of
pharmaceuticals purchased under 340B.
Code
BL
CH

FQHC638
FQHCLA

HM
HV
NH
RWI
RWII
RWIID
RWIIR
RW4
SPNS
UI

Program
Black Lung Clinics Program
Consolidated Community Health Center Cluster Program (includes
Community Health Centers, Migrant Health Centers, Healthcare for the
Homeless Programs, Public Housing Primary Care Programs, and SchoolBased Health Center (Healthy Schools, Healthy Communities) Programs
Tribal Contract/Compact with IHS (P.L. 93-638)
Federally Qualified Health Center Lookalike
NOTE: if your organization is an FQHCLA, you MUST notify OPA if you
are successful in receiving a Section 330 grant at a later date.
Comprehensive Hemophilia Treatment Center
Ryan White Part C
Native Hawaiian Health Care Program
Ryan White Part A
Ryan White Part B
Ryan White ADAP Rebate Option
Ryan White ADAP Direct Purchase
Ryan White Part D
Special Projects of National Significance
Urban Indian

This registration form must be completed and submitted according to the established deadlines that are published on the OPA website (www.hrsa.gov/opa).

Public Burden Statement: An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently
valid OMB control number. The OMB control number for this project Is 0915-XXXX. Public burden is estimated to average XX minutes per respondent, including the time
for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send
comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to HRSA Reports Clearance
Officer, 5600 Fishers Lane, Room 14-33, Rockville, Maryland 20857.


File Typeapplication/pdf
File TitlePHARMACY AFFAIRS BRANCH
AuthorSCHEN
File Modified2012-06-25
File Created2012-06-25

© 2024 OMB.report | Privacy Policy